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LETTERS
Fluoroquinolone-
Resistant Typhoid, 
South Africa 
To the Editor: Salmonella enteri-
ca serotype Typhi, the causal pathogen 
for typhoid, is a major public health 
hazard in many parts of the world, 
with an estimated 21.6 million cases of 
typhoid and 217,000 deaths occurring 
each year (1). Most isolates in South 
Africa are susceptible to quinolones, 
and ﬂ  uoroquinolones remain the treat-
ment of choice (2). The disease is pri-
marily water or foodborne, but person-
to-person spread is well recognized 
(3). Travelers to disease-endemic re-
gions may be at risk for typhoid, which 
may result in the importation of strains 
of S. Typhi with unfamiliar or unusual 
resistance patterns (4). Such infections 
present a challenge to local clinicians 
on optimal patient management.
S.  Typhi was isolated from the 
blood culture of a woman 65 years of 
age from Cape Town; she had been in 
contact with a traveler to Bangladesh. 
The patient was treated ﬁ  rst with cip-
roﬂ   oxacin, but this medication was 
changed to high-dose ceftriaxone com-
bined with doxycycline for 8 days; she 
recovered well. Contact tracing indi-
cated no family members had typhoid 
fever or carried the organism. The per-
son who had traveled to Bangladesh 
was unavailable to provide further 
history or a stool specimen. No other 
potential source of infection could be 
elucidated: the patient lived in an ur-
ban area with safe water sources and 
shared meals with her family.
The isolate was referred to the 
Enteric Diseases Reference Unit for 
conﬁ   rmation of identiﬁ  cation,  sero-
typing (Kauffman-White scheme), 
and antimicrobial drug susceptibility 
testing using the Etest (bioMérieux, 
Marcy l’Étoile, France) and agar dilu-
tion methods, according to criteria of 
the Clinical and Laboratory Standards 
Institute (Wayne, PA, USA) (www.
clsi.org). The isolate was resistant to 
ampicillin, chloramphenicol, sulfame-
thoxazole, nalidixic acid, and cipro-
ﬂ  oxacin, but susceptible to ceftriaxone 
and tetracycline.
Pulsed-ﬁ   eld gel electrophoresis 
(PFGE) analysis was performed on 
the isolate, following the standard 
PulseNet protocol (5). The PFGE pat-
tern was compared with a database of 
S.  Typhi PFGE patterns from South 
Africa by using BioNumerics ver-
sion 6.01 software (Applied Maths, 
Sint-Martens-Latem, Belgium). The 
PFGE pattern of this isolate was 100% 
identical to pattern JPPX01.0026 in 
the Global PulseNet Salmonella Typhi 
Database. This pattern, which has been 
reported to PulseNet from India, Ke-
nya, Tanzania, and Taiwan, is the most 
common pattern in the database (www.
pulsenetinternational.org/projects/
styphidatabase.asp); it is rarely seen in 
South Africa (Figure).
PCR was used to isolate the qui-
nolone resistance-determining region 
(QRDR) of gyrA,  gyrB,  parC, and 
parE ( 6). Genes were sequenced by 
using the BigDye Terminator Cycle 
Sequencing Kit (Applied Biosystems, 
Foster City, CA, USA) and an Applied 
Biosystems 3130 genetic analyzer. The 
QRDR DNA sequences were com-
pared with those of S. Typhi strain Ty2 
(GenBank accession no. AE014613). 
PCR also used to conﬁ  rm the presence 
of  qnrA,  qnrB, and qnrS genes (6). 
Analysis for mutations in the QRDR 
of gyrA, gyrB, parC, and par found a 
single amino-acid mutation (Ser83 to 
Tyr) in gyrA. No amino acid mutations 
were identiﬁ   ed in gyrB,  parC, and 
parE. PCR for detection of qnr genes 
conﬁ  rmed the presence of a qnrS gene, 
which was identiﬁ  ed as the qnrS1 vari-
ant by nucleotide sequence analysis.
The efﬂ   ux of quinolones from 
bacterial cells was investigated in 
the following manner. For nalidixic 
acid and ciproﬂ  oxacin, agar dilution 
MIC testing was performed in the ab-
sence and presence of 40 μg/mL of 
the efﬂ   ux pump inhibitor, Phe-Arg-
β-naphthylamide (6). In the presence 
of efﬂ  ux pump inhibitor, the MIC to 
ciproﬂ  oxacin decreased from 4 μg/mL 
to 1 μg/mL, and the MIC to nalidixic 
acid decreased from >512 μg/mL to 
32  μg/mL, establishing the involve-
ment of an efﬂ  ux pump in conferring 
quinolone resistance.
The mutation in gyrA (Ser83 to 
Tyr) confers reduced susceptibility 
to ciproﬂ  oxacin to a maximum MIC 
≈0.5 μg/mL (7) and the QnrS1 protein 
confers reduced susceptibility to cip-
roﬂ  oxacin to a maximum MIC ≈0.5 
μg/mL (8). We showed that a single 
amino acid mutation in gyrA (Ser83 to 
Tyr) with the QnrS1 protein and active 
efﬂ  ux, conferred ciproﬂ  oxacin resis-
tance, at least to an MIC level of 4 μg/
mL. Previously, Smith et al. reported 
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Figure. Dendrogram of pulsed-ﬁ  eld gel electrophoresis patterns representative of the 15 
largest clusters of Salmonella enterica serotype Typhi isolates identiﬁ  ed in South Africa 
during 2005–2009. The pattern of isolate 372460 is indicated. Scale bar represents 
percentage similarity of pathogens. LETTERS
quinolone resistance in South African 
isolates of S. Typhi mediated by muta-
tions in gyrA and parC in combination 
with active efﬂ  ux (6). We report qnrS1 
from S. Typhi, conﬁ  rming the role of 
plasmid-mediated ﬂ  uoroquinolone re-
sistance in S. Typhi (9) and a ﬂ  uoro-
quinolone-resistant strain in South 
Africa. Fluoroquinolone resistance is 
well recognized in Bangladesh; other 
researchers have described multidrug-
resistant  S.  Typhi isolates imported 
from that country (10). Molecular 
epidemiology supports the conclusion 
that this strain likely originated in Ban-
gladesh (L. Theobald, pers.comm.).
In conclusion, ﬂ  uoroquinolone-
resistant typhoid fever is a reality in 
South Africa in patients who have a 
history of travel or contact with travel-
ers. Blood cultures are mandatory to 
guide antimicrobial drug management. 
Plasmid-mediated ﬂ  uoroquinolone re-
sistance has implications for cotrans-
ference of resistance to the major anti-
microbial agents used to treat typhoid 
fever and for the potential for rapid 
spread of ﬂ  uoroquinolone  resistance 
through S. Typhi strains in South Af-
rica. The presence of ﬂ  uoroquinolone-
resistant typhoid fever could force a 
change in current treatment guidelines 
for this disease. 
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